From: Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab
Study
N (CT/BCT)*
CT ORR
BCT ORR
Risk Ratio
AVF0757 [11]
32/34
18.8%
32.4%
0.58
JO19907 [10]
59/121
33.9%
56.2%
0.60
AVAiL [12]
327/329
21.7%
34.7%
0.63
E4599 [9]
392/381
15.1%
34.9%
0.43
FDA’s meta-analysis [7]
810/865
19.3%
37.7%
0.53
BCD-021-2
NA/206
NA
34.6%